Enchem's NASDAQ Merger Target Granted Conditional Listing; Local Fundraising Gains Momentum

TGHL Receives Conditional Approval to Maintain Listing
Foundation Secured for Merger with Enchem America

Enchem announced on August 4 that The Growth for Human Life (TGHL), a company listed on the NASDAQ and currently pursuing a reverse triangular merger with Enchem's U.S. subsidiary, Enchem America, has received a conditional approval from the NASDAQ hearing panel to maintain its listing.

Exterior view of Enchem Georgia plant. Enchem

According to the Foreign Company Report submitted by TGHL to the U.S. Securities and Exchange Commission, the NASDAQ hearing panel reviewed TGHL’s plan to meet listing requirements and granted an exception, allowing TGHL to maintain its listing on the condition it meets the new NASDAQ listing standards by December 2.

This decision allows TGHL to move forward with the merger with Enchem America and to continue the new NASDAQ listing process for the merged entity. The company explained that the alleviation of uncertainty regarding the listing status of the target company creates more favorable conditions for the upcoming merger and for local funding initiatives.

Previously, Enchem, Enchem America, and TGHL signed a reverse triangular merger agreement last month. Upon completion of the merger, Enchem America will become a wholly owned subsidiary of TGHL, and Enchem is expected to secure an 85% stake in the merged entity on a fully diluted basis.

Enchem is also working in tandem with the merger and new listing procedures to secure at least $200 million in phased funding from global investment institutions. The specific timing and terms of the fundraising will be determined based on the progress of the merger, the results of the NASDAQ review, and negotiations with investment groups.

The funds raised will be used as growth capital for its North American business, including operating capital for its U.S. production base, securing raw materials, expanding supply to clients, and improving production efficiency.

The company added that if the U.S. entity is able to raise growth capital independently at the local level, this will reduce the need for additional investment from Enchem’s headquarters and enhance the head office’s liquidity and financial flexibility.

An Enchem official stated, “This decision by the NASDAQ hearing panel is significant in that it provides a foundation to continue the merger and new listing process together with Enchem America. We will faithfully carry out related procedures and work with global investment institutions to secure at least $200 million in local financing.”

The official added, “By strengthening the independent funding capacity of our U.S. entity, we aim to improve our responsiveness to North American customers and the operating efficiency of our production base, while also enhancing the overall corporate value and financial stability of Enchem.”

This content was produced with the assistance of AI translation services.